# Neuphoria Therapeutics Inc.: Form 20-F for the period ended Jun 30, 2023

- Company: [Neuphoria Therapeutics Inc.](/companies/neup.md) (CIK 1191070)
- Form: 20-F
- Filed: 2023-10-18
- Accepted by EDGAR: Oct 18, 2023, 10:42 ET
- Period: 2023-06-30
- Accession: 0000950170-23-053873
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1191070/000095017023053873/bnox-20230630.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1191070/000095017023053873/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2023-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2022-07-01 to 2023-06-30 | AUD 22.0k | ifrs-full:Revenue |
| Shares outstanding | at 2023-06-30 | 1,486,735,424 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1191070/000095017023053873/bnox-20230630.htm

Filed Oct 18, 2023.
Source: SEC EDGAR, the filing index for accession 0000950170-23-053873. Last ingested by Listed: Oct 24, 2026, 15:10 ET. No prices; not investment advice.